5 Stocks to Watch: Week of 2/9/2026

Whether or not you’re watching the big game, here’s something to spike the football about: 5 high-quality stock picks, all vetted by our Zen Ratings system. We’ve got:

• HCA Healthcare (HCA): America’s hospital powerhouse beats earnings, raises outlook
• Sandisk (SNDK): An AI storage supercycle winner   
• Calix (CALX): Broadband software breakout with massive upside
• Corning (GLW): Glass innovator surging on AI, solar demand
• Halozyme Therapeutics (HALO): Biotech breakout fueled by raised guidance

P.S. Missed last week's picks? Get them here.

A note from our sponsors...

1. Corning Inc (NYSE: GLW)

This company specializes in specialty glass, ceramics, and advanced optics for industrial, scientific, and consumer applications. Its "Springboard" program has driven remarkable success, adding $4B to annualized sales while strong demand for Gen AI and solar products positions Corning for significant future growth.

Zen Rating: B (Buy) — see full analysis

Recent Price: $115.16 — get current quote

Max 1-year forecast: $125.00

Why we're watching:

• Analyst support: 8 analysts we track cover GLW; it has 5 Strong Buy ratings, 1 Buy, and 2 Hold ratings, achieving a Strong Buy consensus. See the ratings
• Citigroup's Asiya Merchant (a top 1% rated analyst) recently maintained her Strong Buy rating with a $120 price target, remaining optimistic about Corning's strong position in the solar market and substantial growth potential from the Apple partnership.
• Susquehanna's Mehdi Hosseini (a top 1% rated analyst) maintained his Strong Buy rating with the highest price target of $125 (+13.27% upside), emphasizing Corning's unique market position and technological advancements in glass manufacturing that bolster its competitive advantage.  
• Argus Research's Jim Kelleher (a top 7% rated analyst) noted that Q3 2025's record-breaking revenue and earnings were driven by continued success in Optical Communications, with management showing optimism about the Springboard program generating an additional $4B to $6B in annual income within three years.
• Industry ranking context: GLW is currently the #7 highest-rated stock in the Electronic Component industry, which has an Industry Rating of A.
• Zen Rating highlights: Buy (B) stocks average +19.88%/yr — in GLW’s case, this is supported by analysts forecasting impressive earnings growth of +95.48% in the next year and revenue growth of +24.3%.
• Component Grades: Corning shows particular strength with an A grade in Momentum and B grades in Value and Financials, while Growth, Sentiment, Safety, and AI components earn C ratings. (See all 7 Zen Component Grades here)

2- Calix (NYSE: CALX)

This cloud and software platform provider is fresh off strong Q4 2025 earnings that exceeded estimates. Additionally, the company has announced an additional $125 million stock repurchase authorization, signaling management confidence in future growth prospects.

Zen Rating: Buy (B) — see full analysis

Recent Price: $452.29 — get current quote

Max 1-year forecast: $90.00

Why we're watching:

• Analyst support: Wall Street maintains unanimous Strong Buy consensus with 3 Strong Buy ratings and 1 Buy rating from 4 analysts covering the broadband technology company. See the ratings
• For example, JP Morgan's Samik Chatterjee (a top 1% rated analyst) recently upgraded the stock to Strong Buy with the highest price target of $90, noting that recent upgrades and new features are expected to drive sales significantly higher next year.
• Rosenblatt analyst Mike Genovese (a top 1% rated analyst) recently maintained his Strong Buy rating with a $70 price target, emphasizing that Calix is positioned to capitalize on new market opportunities due to its strong product portfolio.
• Analysts point to the company's strong earnings beat in Q4 2025, with management highlighting innovation and customer satisfaction as key focus areas driving the business forward.
• Industry ranking context: Calix is currently the #4 highest-rated stock in the App industry, which has an Industry Rating of B.
• Zen Rating highlights: Only the top 20% of stocks receive a B (Buy) rating — CALX is in this class, demonstrating exceptional potential. 
• Component Grades: Acceleration is the name of the game — CALX earns an A for Growth and strong B grades for Financials and from our AI factor. See all 7 Zen Component Grades here

A note from our sponsors...

3- Halozyme Therapeutics (NASDAQ: HALO)

This is sort of like a biopharma technology platform company, with products based on its proprietary enzyme technology that enables subcutaneous delivery of injectable biologics. The company is gaining momentum following strong preliminary 2025 results and raised 2026 guidance, positioning it as a standout value opportunity in the biotech sector.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $77.30 — get current quote

Max 1-year forecast: $92.00

Why we're watching:

• Analyst support: 9 analysts cover HALO. It has 3 Strong Buy, 3 Buy, and 3 Hold ratings, reflecting an overall Buy consensus. See the ratings
• Citizens researcher Jason Butler (a top 2% rated analyst) recently maintained a Buy rating with a $92 price target following strong growth projections in key therapeutic areas, highlighting positive clinical trial outcomes and rising investor confidence.
• HC Wainwright & Co. analyst Mitchell Kapoor (a top 5% rated analyst) reaffirmed his Buy rating at $75, emphasizing robust market demand for HALO's therapies and the company's strategic focus on expanding existing product reach through valuable partnerships.  
• Industry ranking context: HALO is currently the 13th highest-rated stock out of 482 in the Biotech industry — indicating it could be an exceptional pick within a troubled industry (Industry Rating: F).
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — HALO ranks in this elite tier, composed of the top 5% of stocks we track.
• Component Grades: HALO excels with A grades for Value and Financials (not common for a biotech stock), and a strong B from our Artificial Intelligence factor, which sifts through mountains of data to detect subtle patterns that suggest future outperformance that we mere humans might not be able to see. See all 7 Zen Component Grades here

4- Sandisk (NASDAQ: SNDK)

This memory storage company has surged over 1,500% in the past year as AI-driven demand for high-performance storage solutions reaches unprecedented levels, positioning SanDisk as a key beneficiary of the AI infrastructure buildout.

Zen Rating: Strong Buy (A) — see full analysis

Recent Price: $592.03— get current quote

Max 1-year forecast: $800.00

Why we're watching:

• Analyst support: Wall Street maintains a Strong Buy consensus with 9 Strong Buy ratings, 3 Buy ratings, and 4 Hold ratings from 16 analysts we track covering the stock. See the ratings
• For example, Morgan Stanley's Joseph Moore (a top 1% rated analyst) recently maintained his Strong Buy rating with a $690 price target following strong market momentum in the memory sector.
• Cantor Fitzgerald's C.J. Muse (a top 5% rated analyst) recently maintained his Strong Buy rating with the highest price target of $800, citing exceptional shortages and memory service-related price hikes as key catalysts.
• Industry ranking context: SanDisk is currently the #1 highest-rated stock in the Computer Hardware industry, which has an Industry Rating of C.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — SNDK is in this echelon of stocks, but forecasts suggest it could go even higher —  right now, the max forecast suggests nearly 40% potential upside in the coming year.
• Component Grades: The company scores an A for Growth, reflecting strong revenue expansion potential, and an A for Sentiment, indicating robust analyst and market enthusiasm. See all 7 Zen Component Grades here

5- HCA Healthcare (NYSE: HCA)

HCA Healthcare operates 186 hospitals and over 2,000 sites of care across the United States, making it the nation's largest for-profit hospital operator. The company delivered exceptional Q4 results with strong patient volumes and raised guidance, demonstrating resilience in an evolving healthcare landscape.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $513.32 — get current quote

Max 1-year forecast: $598.00

Why we're watching:

• Analyst support: We track 17 analysts who rate the stock — it has 9 Strong Buy ratings, 3 Buy, 4 Hold, and 1 Strong Sell (Overall Buy consensus). See the ratings
• Jefferies' Brian Tanquilut (a top 14% rated analyst) maintained his Strong Buy rating with a $590 price target following the company's strong Q4 performance, representing +18.75% upside potential. 
• Truist Securities' David S Macdonald (a top 11% rated analyst) remains optimistic about HCA's ability to sustain strong patient volume trends while expanding margins through operational improvements.
• Industry ranking context: HCA is currently the #5 highest-rated stock in the Medical Care Facility industry, which has an Industry Rating of A.
• Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — the company's strong competitive position and execution track record support continued outperformance.

Component Grades: HCA demonstrates balanced strength with B grades in Value, Sentiment, Safety, Financials, and AI, though Growth and Momentum earn C ratings as the market digests recent gains. (See all 7 Zen Component Grades here)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.